Measuring the Pancreatic β Cell Mass in Vivo with Exendin SPECT during Hyperglycemia and Severe Insulitis.
Animals
Autoradiography
Diabetes Mellitus, Type 1
/ diagnostic imaging
Disease Models, Animal
Female
Hyperglycemia
/ metabolism
Immunohistochemistry
Indium Radioisotopes
/ administration & dosage
Injections, Intravenous
Insulin-Secreting Cells
/ metabolism
Mice
Mice, Inbred NOD
Pentetic Acid
/ administration & dosage
Peptides
/ administration & dosage
Radiopharmaceuticals
/ metabolism
Tissue Distribution
Tomography, Emission-Computed, Single-Photon
/ methods
GLP-1R
NOD mice
SPECT
exendin
receptor imaging
β cell mass
Journal
Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791
Informations de publication
Date de publication:
03 09 2019
03 09 2019
Historique:
pubmed:
28
7
2019
medline:
9
6
2020
entrez:
27
7
2019
Statut:
ppublish
Résumé
Targeting the glucagon-like peptide-1 receptor with radiolabeled exendin is a very promising method to noninvasively determine the β cell mass in the pancreas, which is needed to unravel the pathophysiology of type 1 and type 2 diabetes. The present study aimed to explore the effects of both hyperglycemia and insulitis on the uptake of exendin in a spontaneous type 1 diabetes mouse model, nonobese diabetic (NOD) mice. NOD mice ( The pancreas could be visualized longitudinally using SPECT. A linear correlation was found between the BCM (%) and pancreatic uptake (%ID/g) as measured by ex vivo counting (Pearson Despite hyperglycemia and severe insulitis, we have found a good correlation between BCM and pancreatic exendin uptake, even in a suboptimal model with relatively high background activity.
Identifiants
pubmed: 31345042
doi: 10.1021/acs.molpharmaceut.9b00728
doi:
Substances chimiques
Indium Radioisotopes
0
Peptides
0
Radiopharmaceuticals
0
exendin 3
130391-54-7
Pentetic Acid
7A314HQM0I
Indium-111
E9NGC49E0T
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM